Weixiu Luo

3.2k total citations · 1 hit paper
18 papers, 1.0k citations indexed

About

Weixiu Luo is a scholar working on Oncology, Genetics and Reproductive Medicine. According to data from OpenAlex, Weixiu Luo has authored 18 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Genetics and 7 papers in Reproductive Medicine. Recurrent topics in Weixiu Luo's work include Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers) and BRCA gene mutations in cancer (4 papers). Weixiu Luo is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers) and BRCA gene mutations in cancer (4 papers). Weixiu Luo collaborates with scholars based in United States, Switzerland and Italy. Weixiu Luo's co-authors include Joyce F. Liu, Ursula A. Matulonis, William T. Barry, Michael J. Birrer, Gini F. Fleming, Mary K. Buss, Ronald J. Buckanovich, Jean Hurteau, S. Percy Ivy and Sreenivasa Nattam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Weixiu Luo

17 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

2014 446 citations Joyce F. Liu, William T. Barry et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weixiu Luo United States	11	659	420	262	203	175	18	1.0k
Martin Pölcher Germany	16	315 0.5×	380 0.9×	184 0.7×	199 1.0×	220 1.3×	37	921
Anne P.G. Crijns Netherlands	16	273 0.4×	138 0.3×	188 0.7×	353 1.7×	95 0.5×	33	1.1k
Kim A. Reiss United States	19	971 1.5×	47 0.1×	452 1.7×	444 2.2×	138 0.8×	63	1.4k
Tyler P. Robin United States	17	608 0.9×	47 0.1×	330 1.3×	198 1.0×	69 0.4×	55	1.3k
Austin Doyle United States	15	423 0.6×	47 0.1×	413 1.6×	99 0.5×	215 1.2×	33	1.0k
Stephanie Markovina United States	17	252 0.4×	80 0.2×	147 0.6×	115 0.6×	65 0.4×	57	845
M.L. Carcangiu Italy	15	390 0.6×	334 0.8×	248 0.9×	439 2.2×	37 0.2×	31	1.1k
Sam Leung Canada	8	238 0.4×	97 0.2×	332 1.3×	244 1.2×	138 0.8×	13	808
Masanori Someya Japan	18	348 0.5×	32 0.1×	277 1.1×	149 0.7×	75 0.4×	70	902
Schlomo Schneebaum Israel	17	574 0.9×	33 0.1×	164 0.6×	225 1.1×	164 0.9×	54	1.1k

Countries citing papers authored by Weixiu Luo

Since Specialization

Citations

This map shows the geographic impact of Weixiu Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weixiu Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weixiu Luo more than expected).

Fields of papers citing papers by Weixiu Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weixiu Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weixiu Luo. The network helps show where Weixiu Luo may publish in the future.

Co-authorship network of co-authors of Weixiu Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Weixiu Luo. A scholar is included among the top collaborators of Weixiu Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weixiu Luo. Weixiu Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Luo, Weixiu, Dong Ye, Kun Zhao, et al.. (2025). Associations between vitamin K and systemic immune and inflammation biomarkers: a population-based study from the NHANES (2007–2020). Frontiers in Nutrition. 12. 1625209–1625209.

2.

Konstantinopoulos, Panagiotis A., Joyce F. Liu, Weixiu Luo, et al.. (2019). Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).. Journal of Clinical Oncology. 37(15_suppl). 5502–5502. 7 indexed citations

3.

Myers, Andrea P., Panagiotis A. Konstantinopoulos, William T. Barry, et al.. (2019). Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer. International Journal of Cancer. 147(2). 413–422. 43 indexed citations

4.

Liu, Joyce F., Christina I. Herold, Kathryn P. Gray, et al.. (2019). Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. JAMA Oncology. 5(12). 1731–1731. 175 indexed citations

5.

Colleoni, Marco, Weixiu Luo, Per Karlsson, et al.. (2017). SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).. Journal of Clinical Oncology. 35(15_suppl). 503–503. 5 indexed citations

6.

Liu, Joyce F., William T. Barry, Michael J. Birrer, et al.. (2017). Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology. 35(15_suppl). 5535–5535. 13 indexed citations

7.

Ribi, Karin, Weixiu Luo, J. Bernhard, et al.. (2015). Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po. Cancer Research. 75(9_Supplement). S3–9. 3 indexed citations

8.

Liu, Joyce F., Jung‐Min Lee, Weixiu Luo, et al.. (2015). A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer.. Journal of Clinical Oncology. 33(15_suppl). 5559–5559. 2 indexed citations

9.

Liu, Joyce F., William T. Barry, Michael J. Birrer, et al.. (2014). Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet Oncology. 15(11). 1207–1214. 446 indexed citations breakdown →

10.

Liu, Joyce F., William T. Barry, Michael J. Birrer, et al.. (2014). A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology. 32(18_suppl). LBA5500–LBA5500. 14 indexed citations

11.

Bernhard, J., Weixiu Luo, Karin Ribi, et al.. (2014). Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).. Journal of Clinical Oncology. 32(15_suppl). 557–557. 10 indexed citations

12.

Liu, Joyce F., William T. Barry, Michael J. Birrer, et al.. (2014). A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology. 32(15_suppl). LBA5500–LBA5500. 10 indexed citations

13.

Fraeman, Kathy, Beth Nordstrom, Weixiu Luo, Sarah Landis, & Sumitra Shantakumar. (2013). Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study. International Journal of Hypertension. 2013. 1–10. 40 indexed citations

14.

Rao, Uma N. M., Sandra J. Lee, Weixiu Luo, Martín C. Mihm, & John M. Kirkwood. (2010). Presence of Tumor-Infiltrating Lymphocytes and a Dominant Nodule Within Primary Melanoma Are Prognostic Factors for Relapse-Free Survival of Patients With Thick (T4) Primary Melanoma. American Journal of Clinical Pathology. 133(4). 646–653. 49 indexed citations

15.

Luo, Weixiu, Beth Nordstrom, Kathy Fraeman, et al.. (2008). Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: Results of a retrospective study of an electronic medical-records database in the United States, 2002–2006. Clinical Therapeutics. 30(12). 2423–2435. 10 indexed citations

16.

Nordstrom, Beth, Weixiu Luo, Kathy Fraeman, Joanna L. Whyte, & Robert J. Nordyke. (2008). Use of Erythropoiesis-Stimulating Agents Among Chemotherapy Patients With Hemoglobin Exceeding 12 Grams Per Deciliter. Journal of Managed Care Pharmacy. 14(9). 858–869. 11 indexed citations

17.

Landis, Daniel M., Weixiu Luo, Jun S. Song, et al.. (2007). Variability Among Breast Radiation Oncologists in Delineation of the Postsurgical Lumpectomy Cavity. International Journal of Radiation Oncology*Biology*Physics. 67(5). 1299–1308. 161 indexed citations

18.

Höchster, Howard S., Weixiu Luo, E Popa, et al.. (2007). Phase II Study of Uracil-Tegafur With Leucovorin in Elderly (≥ 75 years old) Patients With Colorectal Cancer: ECOG 1299. Journal of Clinical Oncology. 25(34). 5397–5402. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact